Menu

Blog

Jun 27, 2021

Compound Tested for Alcoholic Liver Disease

Posted by in category: biotech/medical

Investigators at Cedars-Sinai and UC San Diego found that a synthetic compound given orally protected the liver against injury in an animal model for alcoholic hepatitis.

The study, co-authored by Dr. Ekihiro Seki, was published in the Proceedings of the Na… See More.


The most prevalent forms of ALD are fatty liver, alcoholic hepatitis and cirrhosis. Corticosteroids are the only treatment option for alcoholic hepatitis, or chronic inflammation of the liver, despite little evidence of long-term efficacy and considerable adverse side effects.

Investigators at Cedars-Sinai and the University of California, San Diego (UCSD), found that a synthetic compound given orally protected the liver against injury in an animal model for alcoholic hepatitis. The study was recently published in the Proceedings of the National Academy of Sciences. Ekihiro Seki, MD, PhD of Cedars-Sinai and Dennis A. Carson, MD, of UCSD are co-senior authors of the paper.

“Interleukin-22 (IL-22) is a beneficial cytokine that can help protect the body against invading pathogens, repair damage caused by intestinal or liver disease and potentially prevent the development of ALD,” said Seki, professor of Medicine and Biomedical Sciences.

Leave a reply